Stock Analysis on Net
Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Pfizer Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021
Short-term borrowings, including current portion of long-term debt 2,699 3,890 3,154 4,303 4,295 4,470 6,946 9,699 11,944 8,232 10,350 2,548 3,985 4,188 2,945 4,040 5,990 645 2,241 3,629 3,888 4,352
Trade accounts payable 4,581 4,506 5,240 5,024 5,166 5,240 5,633 5,314 5,106 5,591 6,710 5,338 6,081 6,123 6,809 6,267 6,208 5,506 5,578 4,698 4,327 4,064
Dividends payable 2,451 — 2,445 — 2,445 — 2,437 — 2,380 — 2,372 — 2,315 — 2,303 2,245 2,245 — 2,249 2,191 2,184 —
Income taxes payable 653 3,130 3,103 3,799 3,675 3,105 2,910 2,877 2,884 3,192 2,349 1,898 2,928 1,969 1,587 3,071 3,350 3,177 1,266 4,496 1,742 1,401
Accrued compensation and related items 2,554 2,715 3,610 3,036 2,447 2,607 3,838 3,383 2,566 2,192 2,776 2,372 1,972 2,277 3,407 2,852 1,997 2,249 3,332 2,571 2,015 1,985
Other current liabilities 19,708 20,107 19,432 20,434 19,698 21,030 21,231 21,938 18,939 21,290 23,237 18,980 17,366 22,005 25,087 25,839 27,620 27,691 28,005 24,218 21,508 14,850
Current liabilities 32,646 34,348 36,984 36,596 37,726 36,452 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268 42,671 41,803 35,664 26,652
Long-term debt, excluding current portion 60,495 60,565 61,641 57,409 57,502 57,639 57,405 58,002 57,506 61,307 61,538 61,048 61,356 31,704 32,884 32,629 34,294 35,656 36,195 36,250 35,354 35,347
Pension and postretirement benefit obligations 1,937 1,984 2,041 2,157 2,130 2,021 2,115 2,073 2,040 2,076 2,167 2,166 2,184 2,179 2,250 2,960 3,257 3,494 3,724 4,303 4,939 5,161
Noncurrent deferred tax liabilities 1,964 2,412 2,401 2,467 2,481 2,258 2,122 2,158 2,227 931 640 1,125 1,232 1,067 1,023 616 558 655 349 328 4,161 4,355
Other taxes payable 3,816 3,705 3,591 3,401 3,313 5,724 6,112 5,905 6,532 8,603 8,534 8,099 8,052 9,860 9,812 9,701 10,990 11,574 11,331 11,336 11,259 11,759
Other noncurrent liabilities 14,781 14,200 14,727 13,605 13,931 13,297 14,150 15,569 16,094 15,123 16,540 14,243 13,404 13,009 13,181 12,239 11,312 10,508 9,743 9,201 8,228 6,679
Noncurrent liabilities 82,993 82,866 84,401 79,039 79,357 80,939 81,904 83,707 84,399 88,040 89,419 86,681 86,228 57,819 59,150 58,145 60,411 61,887 61,342 61,418 63,941 63,301
Total liabilities 115,639 117,214 121,385 115,635 117,083 117,391 124,899 126,918 128,218 128,537 137,213 117,817 120,875 94,381 101,288 102,459 107,821 101,155 104,013 103,221 99,605 89,953
Common stock 482 482 481 481 481 481 480 480 480 480 478 478 478 478 476 476 476 476 473 473 472 472
Additional paid-in capital 95,033 94,773 94,469 94,248 94,053 93,856 93,603 93,477 93,197 92,997 92,631 92,496 92,329 92,153 91,802 91,359 91,183 90,844 90,591 89,973 89,336 89,002
Treasury stock (115,194) (115,190) (115,015) (115,011) (115,010) (115,008) (114,763) (114,760) (114,757) (114,755) (114,487) (114,485) (114,482) (114,473) (113,969) (113,945) (113,939) (113,932) (111,360) (111,358) (111,354) (111,348)
Retained earnings 112,087 117,239 114,610 121,149 117,609 119,590 116,725 121,060 116,596 121,318 118,353 126,411 128,796 131,101 125,656 122,966 116,607 111,193 103,394 102,252 96,346 95,158
Accumulated other comprehensive loss (7,218) (7,203) (8,069) (8,066) (8,438) (8,581) (7,842) (7,971) (7,816) (7,758) (7,961) (7,966) (8,102) (8,289) (8,304) (8,225) (7,119) (6,157) (5,897) (5,649) (4,758) (4,664)
Total Pfizer Inc. shareholders’ equity 85,190 90,101 86,476 92,801 88,695 90,338 88,203 92,286 87,700 92,282 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424 77,201 75,691 70,042 68,620
Equity attributable to noncontrolling interests 302 303 299 295 317 299 294 272 275 276 274 270 274 266 255 260 261 261 261 276 273 245
Total equity 85,492 90,404 86,775 93,096 89,012 90,637 88,497 92,558 87,975 92,558 89,288 97,204 99,293 101,236 95,916 92,891 87,469 82,685 77,462 75,967 70,315 68,865
Total liabilities and equity 201,131 207,618 208,160 208,731 206,095 208,028 213,396 219,476 216,193 221,095 226,501 215,021 220,168 195,617 197,204 195,350 195,290 183,840 181,475 179,188 169,920 158,818

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).


The balance sheet reflects a period of significant expansion and structural reallocation of liabilities and equity between April 2021 and June 2026. Total liabilities and equity grew from 158,818 million USD to a peak of 226,501 million USD in December 2023, before moderating to 201,131 million USD by June 2026. This trajectory indicates a substantial increase in the company's capital base, primarily driven by a strategic increase in long-term debt and fluctuating equity levels.

Liability Structure and Debt Management
A profound shift in the debt profile is observed during mid-2023. Long-term debt, excluding the current portion, remained relatively stable around 35,000 million USD until July 2023, at which point it surged to approximately 61,356 million USD. This elevated level of long-term borrowing persisted through June 2026, suggesting a long-term financing strategy or major acquisition funding. Current liabilities exhibited higher volatility, peaking at 47,794 million USD in December 2023, largely influenced by spikes in short-term borrowings and other current liabilities, before declining to 32,646 million USD by the end of the period.
Equity Dynamics and Retained Earnings
Total equity demonstrated a growth phase, rising from 68,865 million USD in April 2021 to a peak of 101,236 million USD in April 2023. This growth was primarily supported by an increase in retained earnings, which climbed from 95,158 million USD to 131,101 million USD over the same period. However, a downward trend in retained earnings emerged after April 2023, ending at 112,087 million USD in June 2026, which contributed to the overall contraction of total equity to 85,492 million USD. Treasury stock remained a significant contra-equity account, consistently offsetting equity by approximately 111,000 to 115,000 million USD throughout the analyzed timeframe.
Other Noncurrent and Current Obligations
Other noncurrent liabilities showed a steady upward trend, increasing from 6,679 million USD in April 2021 to a peak of 16,540 million USD in December 2023, before stabilizing around 14,781 million USD. Conversely, other taxes payable saw a marked decrease, falling from 11,759 million USD in 2021 to 3,816 million USD by June 2026. Pension and postretirement benefit obligations exhibited a consistent downward trend, reducing from 5,161 million USD to 1,937 million USD, indicating a gradual settlement or reduction of these long-term obligations.

Overall, the financial position transitioned from a lower-leverage state in 2021 to a more leveraged structure by 2026. The substantial increase in long-term debt, coupled with the volatility in retained earnings and the persistent impact of treasury stock, characterizes the company's capital management strategy during this period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?